Gordon R. Bernard, M.D., is Chief of Pulmonary Service and Professor of Medicine at Vanderbilt University School of Medicine. In addition, he is Medical Director for the Institutional Review Board. Dr. Bernard is a leader in the area of cardiopulmonary medicine and sepsis research and he has published more than 100 peer-reviewed articles on these topics. He chairs the Steering Committee for NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Dr. Bernard received his M.D. degree from Louisiana State University. He serves on the editorial boards of Clinical Intensive Care, Journal of Critical Care and Sepsis.

Robert W. Buckheit, Jr., Ph.D., is the Director of Infectious Disease and Immunology at TherImmune Research Corporation. Previously, he was the Director of the Microbiology Research Department at Southern Research Institute. Dr. Buckheit received a Ph.D. in Microbiology and Immunology from Duke University and completed a postdoctoral fellowship in Virology, Cell and Microbiology at the University of North Carolina. Dr. Buckheit has received numerous honors and awards in the areas of cancer and viral research.

Stan Bukofzer, M.D., is Divisional Vice President and Head of Global Medical Affairs of Abbott Laboratories, where he is responsible for health economics and outcomes, physician development, affiliate medical departments as well as Abbott’s internal contract research organization. Dr. Bukofzer has also served as the head of Abbott’s Anti-Infectives Venture and as the medical director of clinical research for Abbott International. Prior to joining Abbott, he practiced gastroenterology and was involved in research into molecular aspects of the Hepatitis B virus.

James A. Longstreth, Ph.D. is the founder and president of Longstreth & Associates, Inc., a company specializing in assisting the pharmaceutical industry in the management of pharmacokinetic aspects of the drug development and life cycle management processes. His expertise is in the design, implementation and analysis of animal and human trials for the identification of the time course of critical indicators of a drug’s presence and its performance. He is also an expert at integrating pharmacokinetic and pharmacodynamic findings into IND, NDA and Supplemental New Drug Application filings with the FDA and other international regulatory bodies. Dr. Longstreth received his Ph.D. in Biomedical Engineering from The Johns Hopkins University and is an author on over 30 articles and book chapters. Dr. Longstreth’s previous experience includes a faculty position at the University of North Carolina School of Pharmacy and employment at G.D. Searle.

Renslow D. Sherer, Jr., M.D., is Clinical Associate at the University of Chicago Hospitals. He was Director of Coordinated HIV Services at the CORE Center, Cook County Hospital. He has extensive experience and expertise in HIV primary care and in model care programs for women, chemical dependency, and the medically indigent. He has been active in HIV clinical research and in the design and implementation of clinical trials, in HIV prevention programs, and in local and federal policy on HIV disease. In September, 2003 he became the Director of HIV/STI/TB for Project HOPE and he joined the faculty of the Section of Infectious Diseases at the University of Chicago. Dr. Sherer received an M.D. degree from Rush University and is a Diplomat of the American Board of Internal Medicine. Dr. Sherer has published extensively in the area of HIV and AIDS and has been a member of numerous committees, task forces and panels on AIDS. He is the recipient of the Albert Ebert award presented by the National Pharmacist Honor Society and a member of the Department of Health and Human Services AIDS Treatment Guideline Panel.

Stacy N. Suberg, Ph.D., is the founder of a regulatory consulting group, Research-Based Regulatory, Ltd., providing regulatory services in the areas of human drugs, biologics, medical devices and veterinary drugs. Clients include multi-billion dollar pharmaceutical companies, biotech start-ups, academic institutions, law firms and other life science companies. Dr. Suberg is also actively involved with the biologics group at the FDA with expertise in the area of cellular therapies. Dr. Suberg was employed with Searle and Bristol-Myers prior to starting her own company. She received her Ph.D. in Physiology from the University of California-Davis.

Nicholas J. Vogelzang, M.D., is Director of the Nevada Cancer Institute. He was formerly Director of the University of Chicago Cancer Research Center, Professor of Medicine and Surgery (Urology) and the Buffet Chair in Genitourinary Oncology at the University of Chicago. Dr. Vogelzang is a leading researcher in the area of oncology. He received his M.D. from the University of Illinois at Chicago and completed a fellowship in Medical Oncology at the University of Minnesota. Dr. Vogelzang has served on the board of directors for the American Cancer Society and the American Society of Clinical Oncology, the Editorial Review Board for Cancer Research and is a member of the Illinois State Legislative Committee of the American Association for Cancer Research. He has over 250 publications and is the senior editor of the Comprehensive Textbook of Genitourinary Oncology.

Mark A. Wainberg, Ph.D., is the Director of Research of the Lady Davis Institute for Medical Research at the Jewish General Hospital in Montreal, Canada. He received a B.S. degree from McGill University and a Ph.D. degree from Columbia University. Dr. Wainberg has received numerous awards and honors and has published extensively in the areas of HIV and cancer. The antiviral activity of the HIV drug 3TC was first identified in Dr. Wainberg’s laboratory. Dr. Wainberg was the President of the International AIDS Society between 1998-2000. Additionally, he is Professor and Director of the McGill AIDS Centre and Professor of Microbiology and Immunology at McGill University.

Herbert P. Wiedemann, M.D., is Chairman of the Department of Pulmonary, Allergy & Critical Care Medicine at The Cleveland Clinic. Dr. Wiedemann received his M.D. from Cornell University and completed a postdoctoral fellowship in pulmonary and critical care medicine at Yale University. Dr. Wiedemann has conducted extensive research in the area of ARDS and has been principal investigator for several clinical studies sponsored by major pharmaceutical companies. He serves on the editorial boards for Cleveland Clinic Journal of Medicine, Clinical Pulmonary Medicine and Evidenced-Based On-Call.